<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04581473</url>
  </required_header>
  <id_info>
    <org_study_id>CT041-ST-01</org_study_id>
    <nct_id>NCT04581473</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection</brief_title>
  <official_title>An Open, Multicenter, Phase Ib/II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection in Patients With Advanced Gastric/ Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CARsgen Therapeutics Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CARsgen Therapeutics Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open, multicenter, phase Ib/II study to evaluate the efficacy, safety and pharmacokinetics&#xD;
      of CT041 autologous CAR T-cell injection in patients with advanced gastric/ gastroesophageal&#xD;
      junction adenocarcinoma and pancreatic cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open, multicenter, Phase Ib/II clinical trial evaluating chimeric antigen&#xD;
      receptor-modified autologous T cells targeting CLDN18.2 (CT041 autologous CAR T) in subjects&#xD;
      with Claudin18.2 (CLDN18.2) expression-positive, advanced gastric/esophagogastric combination&#xD;
      adenocarcinoma that has failed at least second-line therapy and advanced pancreatic cancer&#xD;
      that has failed at least first-line therapy. Cells, which will be referred to in the text as&#xD;
      CT041) for effectiveness, safety and cellular metabolic kinetics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ib study dose exploration stage: Incidence of Treatment Related adverse events (AEs)</measure>
    <time_frame>day1-month 12</time_frame>
    <description>Incidence of treatment related AEs, AEs of special interest and serious adverse events(SAEs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib study dose exploration stage: Identification of Maximum Tolerated Dose (MTD)</measure>
    <time_frame>day1-day28</time_frame>
    <description>Incidence of dose-limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib study dose expansion stage and Phase II study: ORR Antitumor efficacy-Objective response rate(ORR)</measure>
    <time_frame>day 1-week 24</time_frame>
    <description>Rate of best response to PR and CR as assessed by RECISIT 1.1 criteria) based on IRC evaluation within 24 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase Ib study dose exploration stage: Antitumor efficacy-Objective response rate (ORR)</measure>
    <time_frame>month 12</time_frame>
    <description>The number of cases in which tumor size is reduced to PR or CR / the total number of evaluable cases (%). In the event of PR or CR, assessed by RECISIT 1.1 criteria) within 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib study dose exploration stage: Antitumor efficacy-Disease control rate (DCR)</measure>
    <time_frame>month 12</time_frame>
    <description>The number of cases in which response are achieved from the start of cell infusion/the total number of evaluable cases (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib study dose exploration stage: Antitumor efficacy-Duration of response (DOR)</measure>
    <time_frame>month 12</time_frame>
    <description>The period from the first evaluation of CR or PR to the first evaluation of PD or death of any causeinfusion/the total number of evaluable cases (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib study dose exploration stage: Antitumor efficacy-Duration of disease control (DDC)</measure>
    <time_frame>month 12</time_frame>
    <description>The period from the first evaluation of clinical benefit to the first evaluation of PD or any cause of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib study dose exploration stage: Antitumor efficacy-Progression-free survival (PFS)</measure>
    <time_frame>month 12</time_frame>
    <description>The period from the day when the subject receives the infusion of cells to the first recorded tumor progression (whether treated or not) or death of any cause, which occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib study dose exploration stage: Antitumor efficacy-Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>The period from the first infusion to any cause of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib study dose exploration stage: Pharmacokinetics (the number of cell copies and cell persistence duration in peripheral blood)</measure>
    <time_frame>month 12</time_frame>
    <description>CAR-CLDN18.2 DNA in peripheral blood detected by q-PCR at each visit after infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib study dose expansion stage and Phase II study: Antitumor efficacy-Objective response rate (ORR)</measure>
    <time_frame>month 12</time_frame>
    <description>Rate of best response to PR and CR as assessed by RECISIT 1.1 criteria) based on IRC evaluation after infusion of CT041 cells,assessed by RECISIT 1.1 criteria) based assessed by RECISIT 1.1 criteria) based on IRC evaluation after infusion of CT041 cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib study dose expansion stage and Phase II study: Antitumor efficacy-Disease control rate (DCR)</measure>
    <time_frame>month 12</time_frame>
    <description>The number of cases in which response are achieved from the start of cell infusion/the total number of evaluable cases (%), assessed by RECISIT 1.1 criteria based on IRC evaluation after infusion of CT041 cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib study dose expansion stage and Phase II study: Antitumor efficacy-Progression-free survival (PFS)</measure>
    <time_frame>month 12</time_frame>
    <description>The period from the day when the subject receives the infusion of cells to the first recorded tumor progression (whether treated or not) or death of any cause, which occurs first,assessed by RECISIT 1.1 criteria based on IRC evaluation after infusion of CT041 cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib study dose expansion stage and Phase II study: Antitumor efficacy-Duration of response (DOR)</measure>
    <time_frame>month 12</time_frame>
    <description>The period from the first evaluation of CR or PR to the first evaluation of PD or death of any cause, assessed by RECISIT 1.1 criteria based on IRC evaluation after infusion of CT041 cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib study dose expansion stage and Phase II study: Antitumor efficacy-Duration of disease control (DDC)</measure>
    <time_frame>month 12</time_frame>
    <description>The period from the first evaluation of clinical benefit to the first evaluation of PD or any cause of death,assessed by RECISIT 1.1 criteria based on IRC evaluation after infusion of CT041 cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib study dose expansion stage and Phase II study: Antitumor efficacy-Overall survival (OS)</measure>
    <time_frame>month 12</time_frame>
    <description>The period from the first infusion to any cause of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib study dose expansion stage and Phase II study: Pharmacokinetics (the number of cell copies and cell persistence duration in peripheral blood)</measure>
    <time_frame>month 12</time_frame>
    <description>CAR-CLDN18.2 DNA in peripheral blood detected by q-PCR at each visit after infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib study dose expansion stage and Phase II study:Incidence of Treatment Related adverse events (AEs)</measure>
    <time_frame>day1-day28</time_frame>
    <description>Incidence of treatment related AEs, AEs of special interest and serious adverse events(SAEs).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>CT041 autologous CAR T-cell injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study will be divided into three phases, phase Ib dose exploration phase and dose extension phase and phase II effectiveness and safety confirmation phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT041 autologous CAR T-cell injection</intervention_name>
    <description>1-3 CT041 autologous CAR T-cell injection infusion</description>
    <arm_group_label>CT041 autologous CAR T-cell injection</arm_group_label>
    <other_name>CAR T-cell injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be willing to participate in a clinical trial; have full knowledge of the study, be&#xD;
             informed and sign informed consent; and be willing to follow and be able to complete&#xD;
             all trial procedures;&#xD;
&#xD;
          2. Aged 18 to 75 years, either sex;&#xD;
&#xD;
          3. Patients with pathologically diagnosed advanced gastric/ gastroesophageal junction&#xD;
             adenocarcinoma who have failed second-line treatment at least; or patients with&#xD;
             pathologically diagnosed advanced pancreatic cancer who have failed first-line&#xD;
             treatment at least;&#xD;
&#xD;
          4. Tumor tissue samples were positive for CLDN18.2 IHC staining&#xD;
&#xD;
          5. Estimated life expectancy &gt;12 weeks;&#xD;
&#xD;
          6. According to the RECIST 1.1, there is measurable tumor lesions;&#xD;
&#xD;
          7. ECOG physical status score 0 ~ 1 at screening, within 24 hours prior to apheresis, and&#xD;
             at baseline&#xD;
&#xD;
          8. Sufficient venous access for mononuclear cell collection&#xD;
&#xD;
          9. Unless otherwise specified, patients should meet the certain conditions prior to&#xD;
             screening and pre-treatment and be allowed one week to retest if an abnormal&#xD;
             laboratory test does not meet the criteria, and if the criteria are still not met, the&#xD;
             screening is considered to have failed:&#xD;
&#xD;
         10. Female patients of childbearing age must undergo a serum pregnancy test at screening&#xD;
             and prior to pretreatment and the results must be negative, and are willing to use a&#xD;
             very effective and reliable method of contraception within 1 year after the last study&#xD;
             treatment.&#xD;
&#xD;
         11. Men who have actively sexual intercourse with women with child-bearing potential, must&#xD;
             agree to use barrier-based contraception if they have no vasectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women;&#xD;
&#xD;
          2. HIV, Treponema pallidum or HCV serologically positive;&#xD;
&#xD;
          3. Any uncontrollable active infection, including but not limited to active tuberculosis,&#xD;
             HBV infection;&#xD;
&#xD;
          4. The side effects caused by the previous treatment of the subjects did not return to&#xD;
             CTCAE ≤1; except hair loss and other tolerable events determined by investigator;&#xD;
&#xD;
          5. Patients known to have active autoimmune diseases, including but not limited to&#xD;
             psoriasis or rheumatoid arthritis, or other diseases requiring long-term&#xD;
             immunosuppressive therapy;&#xD;
&#xD;
          6. Previously allergic to immunotherapy and related drugs,history of severe allergies, or&#xD;
             allergic to components of CT041.&#xD;
&#xD;
          7. Previously received any chimeric antigen receptor-modified T-cells (including CAR-T,&#xD;
             TCR-T);&#xD;
&#xD;
          8. Patients have brain metastasis or symptoms of brain metastasis;&#xD;
&#xD;
          9. Patients at high risk of hemorrhage or perforation;&#xD;
&#xD;
         10. Patients requiring anticoagulant therapy;&#xD;
&#xD;
         11. Patients requiring continuous anti-platelet therapy;&#xD;
&#xD;
         12. Patients with a history of organ transplantation or awaiting organ transplantation;&#xD;
&#xD;
         13. Patients who have undergone major surgery or significant trauma within 4 weeks prior&#xD;
             to apheresis, or who are expected to undergo major surgery during the study;&#xD;
&#xD;
         14. Presence of other serious pre-existing medical conditions that may limit patient&#xD;
             participation in the study;&#xD;
&#xD;
         15. The investigator assessed that the patient was unable or unwilling to comply with the&#xD;
             requirements of the study protocol;&#xD;
&#xD;
         16. Prior to pretreatment, patients developed, including but not limited to, new&#xD;
             arrhythmias that could not be controlled with drugs, hypotension requiring pressor&#xD;
             agent, bacterial, fungal or viral infections that required intravenous antibiotics.&#xD;
             The investigator judges that the patient is not suitable for continuing the trial.&#xD;
             Patients who use antibiotics to prevent infection can continue the trials if judged by&#xD;
             the investigator;&#xD;
&#xD;
         17. The patient has a central nervous system disease sign or an abnormal neurological test&#xD;
             result with clinical significance;&#xD;
&#xD;
         18. The patient is currently suffered from or have suffered from other incurable malignant&#xD;
             tumors within previous 3 years, except in situ cervical cancer or skin basal cell&#xD;
             cancer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xianjun Yu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zonghai Li, MD</last_name>
    <phone>86-21-54489926</phone>
    <phone_ext>817</phone_ext>
    <email>zonghaili@carsgen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yilin Wang</last_name>
    <phone>86-21-64501828</phone>
    <email>yilinwang@carsgen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shen Lin, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xianju Yu, Professor</last_name>
    </contact>
    <contact_backup>
      <last_name>Jian Zhang, Professor</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi Ba, Professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced solid tumors</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Esophagogastric Junction Cancer</keyword>
  <keyword>Claudin 18.2</keyword>
  <keyword>CLDN18.2</keyword>
  <keyword>Car T cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

